Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company focused on medicines for HIV, viral hepatitis, COVID‑19, cancer and inflammation. The GILD news feed highlights how the company’s research, collaborations and policy decisions translate into clinical programs, regulatory milestones and access initiatives across these therapeutic areas.
Investors and healthcare observers following GILD news will see regular updates on Gilead’s HIV portfolio, including clinical trial readouts such as the Phase 3 ARTISTRY‑1 and ARTISTRY‑2 studies of an investigational single‑tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. News also covers developments related to lenacapavir as a long‑acting option for HIV prevention and treatment, as well as agreements affecting key products like Biktarvy, including patent settlements disclosed by the company.
Oncology and cell therapy news is another major theme. Through Kite, a Gilead company, GILD‑related releases feature data on Yescarta for relapsed or refractory large B‑cell lymphoma, next‑generation bicistronic CAR T‑cell candidates KITE‑753 and KITE‑363 for B‑cell lymphomas, and anitocabtagene autoleucel (anito‑cel) for relapsed or refractory multiple myeloma. Updates often include efficacy and safety results from pivotal and early‑stage trials, as well as details on collaborations such as the partnership with Arcellx on anito‑cel and the research collaboration with OncoNano Medicine on ON‑BOARD encapsulation technology.
Gilead news also reflects broader corporate and policy activity, including agreements with the U.S. government related to drug pricing and access, philanthropic grants from the Gilead Foundation for metastatic breast cancer support, leadership appointments, investor conference presentations and quarterly financial announcements. Bookmark this page to monitor how these scientific, commercial, governance and access‑related developments shape the ongoing story of GILD.
Gilead Sciences (Nasdaq: GILD) will present at multiple investor conferences in May–June 2026. Scheduled presentations include BofA Health Care (May 12, 2:20 PM PT), RBC Global Healthcare (May 19, 11:00 AM ET), Bernstein Strategic Decisions (May 28, 11:00 AM ET) and Goldman Sachs Global Healthcare (June 9, 1:20 PM ET).
Live webcasts are available on the company investor site and replays will be accessible for at least 30 days following each presentation.
Gilead Sciences (NASDAQ: GILD) announced the FDA accepted its NDA for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) and granted priority review with a PDUFA action date of August 27, 2026.
Phase 3 ARTISTRY-1 and ARTISTRY-2 showed comparable Week 48 maintenance of virologic suppression and generally favorable tolerability; BIC/LEN remains investigational and not approved.
Gilead Sciences (Nasdaq: GILD) completed its acquisition of Arcellx (Nasdaq: ACLX) on April 28, 2026, buying Arcellx for $115 cash per share plus one $5 CVR, implying approximately $7.8 billion equity value.
The CVR pays if cumulative global net sales of anito-cel reach $6.0 billion through 2029. Arcellx becomes a Gilead subsidiary and its common stock will be delisted. Gilead expects 2026 diluted EPS to decline by $5.57–$5.67 and forecasts modest dilution in 2026–2027, with accretion in 2028+ subject to FDA approval of anito-cel.
Gilead Sciences (Nasdaq: GILD) will release its first quarter 2026 financial results on Thursday, May 7, 2026 after the market close. Management will host a live webcast at 4:30 p.m. ET that day to discuss results and provide a business update. The webcast will be archived on Gilead's investor site for one year.
Gilead (Nasdaq: GILD) said all required regulatory approvals for its acquisition of Arcellx have been obtained and extended the tender offer deadline to 5:00 p.m. ET on April 27, 2026. The offer remains $115.00 cash per share plus one CVR potentially worth $5.00 payable March 31, 2030, if cumulative worldwide sales of anito-cel exceed $6.0 billion by December 31, 2029. As of 4:00 p.m. ET on April 16, 2026, ~10,271,823 shares (about 17.5%) were validly tendered. The transaction still requires customary closing conditions including a majority of outstanding Arcellx shares being tendered.
Gilead (Nasdaq: GILD) said PEPFAR and The Global Fund will further invest to expand access to its twice-yearly injectable HIV prevention medicine lenacapavir, reaching an additional 1 million people and bringing total commitment to up to 3 million people through 2028.
The company said lenacapavir shipments began in late 2025, Gilead is supplying doses at no profit to these partners, and broad generic rollout is expected in 2027 via voluntary licenses with six manufacturers.
Tempus (NASDAQ:TEM) announced an expanded, multi-year collaboration with Gilead (NASDAQ:GILD) to advance oncology R&D using real-world evidence and AI. The agreement gives Gilead enterprise-wide access to Tempus' Lens platform, broader multimodal datasets across multiple indications, and dedicated Tempus analytical services.
This collaboration targets trial design, indication selection, biomarker strategy, and health outcomes analysis to inform clinical decision-making and support oncology pipeline development.
Gilead (Nasdaq: GILD) agreed to acquire Tubulis for $3.15 billion upfront plus up to $1.85 billion in contingent milestones, expanding Gilead’s antibody-drug conjugate (ADC) capabilities and oncology pipeline. The deal adds lead candidate TUB-040 (NaPi2b TOPO1i ADC, Phase 1b/2) and TUB-030.
Gilead plans to finance the transaction with cash on hand and senior unsecured notes; closing is expected in Q2 2026 and is subject to customary conditions.
Gilead (Nasdaq: GILD) extended its tender offer for Arcellx common stock to 5:00 p.m. ET on April 24, 2026. The offer remains $115.00 cash per share plus one CVR entitling holders to a possible $5.00 payment if anito-cel cumulative worldwide sales exceed $6.0 billion by December 31, 2029.
As of 5:00 p.m. ET on March 31, 2026, approximately 4,389,763 shares (about 7.5%) were validly tendered. The transaction is expected to close in Q2 2026, subject to customary conditions including majority tender and regulatory approvals.
Gilead Sciences (Nasdaq: GILD) agreed to acquire Ouro Medicines for $1,675 million upfront plus up to $500 million in contingent milestones, adding OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager targeting autoimmune diseases.
Gilead expects OM336 to enter registrational studies in 2027, and is in advanced talks with Galapagos for a collaboration where Galapagos funds 50% of upfront and development costs and receives 20%-23% royalties.